Littérature scientifique sur le sujet « Pharmacokinetic interactions »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Pharmacokinetic interactions ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Pharmacokinetic interactions"
Taylor, David. « Pharmacokinetic interactions involving clozapine ». British Journal of Psychiatry 171, no 2 (août 1997) : 109–12. http://dx.doi.org/10.1192/bjp.171.2.109.
Texte intégralKeirns, J., T. Sawamoto, M. Holum, D. Buell, W. Wisemandle et A. Alak. « Steady-State Pharmacokinetics of Micafungin and Voriconazole after Separate and Concomitant Dosing in Healthy Adults ». Antimicrobial Agents and Chemotherapy 51, no 2 (20 novembre 2006) : 787–90. http://dx.doi.org/10.1128/aac.00673-06.
Texte intégralSoyata, Amelia, Aliya Nur Hasanah et Taofik Rusdiana. « Interaction of Warfarin with Herbs Based on Pharmacokinetic and Pharmacodynamic Parameters ». Indonesian Journal of Pharmaceutics 2, no 2 (5 juin 2020) : 69. http://dx.doi.org/10.24198/idjp.v2i2.27289.
Texte intégralCostache, Irina-Iuliana, Anca Miron, Monica Hăncianu, Viviana Aursulesei, Alexandru Dan Costache et Ana Clara Aprotosoaie. « Pharmacokinetic Interactions between Cardiovascular Medicines and Plant Products ». Cardiovascular Therapeutics 2019 (2 septembre 2019) : 1–19. http://dx.doi.org/10.1155/2019/9402781.
Texte intégralERESHEFSKY, LARRY, STEPHEN R. SAKLAD, MARK D. WATANABE, CHESTER M. DAVIS et MICHAEL W. JANN. « Thiothixene Pharmacokinetic Interactions ». Journal of Clinical Psychopharmacology 11, no 5 (octobre 1991) : 296???301. http://dx.doi.org/10.1097/00004714-199110000-00004.
Texte intégralHartshorn, Edward A. « Pharmacokinetic Drug Interactions ». Journal of Pharmacy Technology 1, no 5 (septembre 1985) : 193–99. http://dx.doi.org/10.1177/875512258500100505.
Texte intégralEichelbaum, Michel. « Pharmacokinetic Drug Interactions ». Journal of Clinical Pharmacology 26, no 6 (8 juillet 1986) : 469–73. http://dx.doi.org/10.1002/j.1552-4604.1986.tb03560.x.
Texte intégralPukrittayakamee, Sasithon, Joel Tarning, Podjanee Jittamala, Prakaykaew Charunwatthana, Saranath Lawpoolsri, Sue J. Lee, Warunee Hanpithakpong et al. « Pharmacokinetic Interactions between Primaquine and Chloroquine ». Antimicrobial Agents and Chemotherapy 58, no 6 (31 mars 2014) : 3354–59. http://dx.doi.org/10.1128/aac.02794-13.
Texte intégralCohen, Lawrence J., et C. Lindsay DeVane. « Clinical Implications of Antidepressant Pharmacokinetics and Pharmacogenetics ». Annals of Pharmacotherapy 30, no 12 (décembre 1996) : 1471–80. http://dx.doi.org/10.1177/106002809603001216.
Texte intégralMarvanova, Marketa. « Pharmacokinetic characteristics of antiepileptic drugs (AEDs) ». Mental Health Clinician 6, no 1 (1 janvier 2016) : 8–20. http://dx.doi.org/10.9740/mhc.2015.01.008.
Texte intégralThèses sur le sujet "Pharmacokinetic interactions"
McArdle, Elizabeth Karen. « Pharmacokinetic interactions of constituents of cannabis extracts ». Thesis, University of Aberdeen, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.415480.
Texte intégralRaaska, Kari. « Pharmacokinetic interactions of clozapine in hospitalized patients ». Helsinki : University of Helsinki, 2003. http://ethesis.helsinki.fi/julkaisut/laa/kliin/vk/raaska/.
Texte intégralLundahl, Anna. « In vivo Pharmacokinetic Interactions of Finasteride and Identification of Novel Metabolites ». Doctoral thesis, Uppsala universitet, Institutionen för farmaci, 2010. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-129362.
Texte intégralAdedoyin, A. P. « Pharmacokinetic drug-drug interactions : inhibition and induction studies in the rat ». Thesis, University of Manchester, 1986. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.376236.
Texte intégralElsherbiny, Doaa. « Pharmacokinetic drug-drug interactions in the management of malaria, HIV and tuberculosis ». Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis, 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-8426.
Texte intégralYadav, Jaydeep. « EVALUATING PHARMACOKINETIC DRUG-DRUG INTERACTIONS DUE TO TIME DEPENDENT INHIBITION OF CYTOCHROME P450s ». Diss., Temple University Libraries, 2018. http://cdm16002.contentdm.oclc.org/cdm/ref/collection/p245801coll10/id/524248.
Texte intégralPh.D.
Time-dependent inactivation (TDI) of CYPs is a leading cause of clinical drug-drug interactions (DDIs). Current methods tend to over-predict DDIs. In this study, a numerical approach was used to model complex CYP3A TDI in human liver microsomes. Inhibitors evaluated include troleandomycin (TAO), erythromycin (ERY), verapamil (VER), Paroxetine (PAR), itraconazole (ITZ) and diltiazem (DTZ) along with primary metabolites N-demethyl erythromycin (NDE), norverapamil (NV), and N-desmethyl diltiazem (MA). Complexities incorporated in the models included multiple binding kinetics, quasi-irreversible inactivation, sequential metabolism, inhibitor depletion, and membrane partitioning. The different factors affecting TDI kinetics were evaluated such as lipid partitioning, inhibitor depletion, presence of transporters. The inactivation parameters obtained from numerical method were incorporated into static in-vitro – in-vivo correlation (IVIVC) models to predict clinical DDIs. For 123 clinically observed DDIs, using a hepatic CYP3A synthesis rate constant of 0.000146 min-1, the average fold difference between observed and predicted DDIs was 2.97 for the standard replot method and 1.66 for the numerical method. Similar results were obtained using a synthesis rate constant of 0.00032 min-1. These results suggest that numerical methods can successfully model complex in-vitro TDI kinetics and that the resulting DDI predictions are more accurate than those obtained with the standard replot approach. Chapter one presents the detailed introduction along with the hypothesis and significance of the project. Chapter 2 includes the development of the bioanalytical method for quantitation of various compounds which includes inactivators and their primary metabolites. Chapter 3 entails the discussion on in-vivo studies in rats involving TDI mediated DDI studies. Chapter 4 discusses the in-vitro studies and use of the numerical method for evaluation of TDI kinetics. Chapter 5 and chapter 6 provides discussion on the impact of inhibitor depletion and partitioning of TDI kinetics and how these two could lead to misinterpretation of TDI results. Chapter 6 also provides a discussion on how transporters could affect TDI results mainly from hepatocyte studies. Chapter 7 involves prediction of TDI mediated DDI using static modeling. Chapter 8 is a case study on bosentan involving induction mediated DDI.
Temple University--Theses
Cherkaoui, Rbati Mohammed. « Mathematical and physical systems biology : application to pharmacokinetic drug-drug interactions and tumour growth ». Thesis, University of Nottingham, 2016. http://eprints.nottingham.ac.uk/33719/.
Texte intégralNaghmeh, Jabarizadekivi. « A Comparison of the Effect of Omeprazole and Rabeprazole on Clozapine Serum Concentrations ». University of Sydney, 2008. http://hdl.handle.net/2123/2471.
Texte intégralClozapine is a drug of choice for treatment of refractory schizophrenia, which is primarily metabolized by Cytochrome P450 1A2 (CYP1A2). Norclozapine is its main metabolite. There are reports of wide ranging gastrointestinal side effects associated with clozapine therapy, that result in concomitant administration of proton pump inhibitors to treat acid-related disorders. Omeprazole is an established CYP1A2 inducer, while an in vitro study has shown that rabeprazole is much less potent in this regard. There is no available information about the impact of rabeprazole on CYP1A2 activity in patients. Firstly, this information is essential when prescriptions are changed from omeprazole to rabeprazole to reduce medication costs. Therefore, the aim of this study was to compare the effects of rabeprazole and omeprazole on CYP1A2-mediated clearance (CL/F) of clozapine. Secondly, the effective dosage of clozapine varies widely among patients, making it necessary to individualize drug therapy with clozapine. The reason for dosage variation could be due to the influence of patient-related variables on clozapine plasma concentrations. Therefore, another aim of this study was to investigate the relationship between patient variables, such as age, gender, cigarette smoke, weight and body mass index and clozapine clearance (CL/F). A cross-over study design was used for this study. Twenty patients from Macquarie hospital who were receiving clozapine and rabeprazole (with no other interacting medications) were recruited in this study. Blood samples were taken at 30 min, 1 hr, 2 hr and 12 hr after a dose of clozapine. Rabeprazole was then replaced with omeprazole. After at least 1 month blood samples were again collected at the above corresponding intervals after clozapine. The plasma concentrations of clozapine and norclozapine were determined by high performance liquid chromatography. Abbottbase Pharmacokinetic Systems Software, which utilizes Bayesian forecasting, was used to estimate pharmacokinetic parameters of clozapine. The ratio of plasma norclozapine/clozapine concentrations at trough level was used to reflect CYP1A2 activity. No difference was observed in clozapine clearance (CL/F) and CYP1A2 activity during concurrent therapy with either rabeprazole or omeprazole. According to some studies CYP1A2 induction by omeprazole is dose dependent. Furthermore, since rabeprazole is a weak CYP1A2 inducer in vitro, we conclude that omeprazole and rabeprazole may not induce CYP1A2 activity when used at conventional therapeutic dosage (<40 mg/day). Hence, replacement of omeprazole with rabeprazole at conventional therapeutic dosages (20 or 40 mg daily) offers no advantages in the management of patients with schizophrenia on clozapine and no dose adjustment is required. Consistent with previous studies, clozapine concentrations were found to be significantly lower in cigarette smokers due to CYP1A2 induction. No relationship was found between age, gender, or weight and clozapine clearance (CL/F). However, body mass index showed a significant negative correlation with clozapine clearance (CL/F). Since weight gain and lipid accumulation are common side effects of clozapine they may be associated with a reduction of CYP1A2 activity and clozapine clearance (CL/F). Moreover, high lipoprotein levels may decrease the unbound fraction of clozapine and decrease the availability of clozapine for oxidation by cytochrome P450 enzymes. Therefore, it is concluded that omeprazole and rabeprazole may not induce CYP1A2 activity when used at conventional therapeutic dosage (<40mg/day). Hence, replacement of omeprazole with rabeprazole does not require the dose of clozapine to be adjusted. Moreover, the negative correlation between clozapine clearance (CL/F) and BMI is informative. Further studies are now required to clarify the relationship between BMI, lipoprotein levels and clozapine clearance in patients with schizophrenia.
Naghmeh, Jabarizadekivi. « A Comparison of the Effect of Omeprazole and Rabeprazole on Clozapine Serum Concentrations ». Thesis, The University of Sydney, 2007. http://hdl.handle.net/2123/2471.
Texte intégralSalem, Farzaneh. « Applications of physiologically based pharmacokinetic modelling to prediction of the likelihood of metabolic drug interactions in paediatric population and studying disparities in pharmacokinetics between children and adults ». Thesis, University of Manchester, 2014. https://www.research.manchester.ac.uk/portal/en/theses/applications-of-physiologically-based-pharmacokinetic-modelling-to-prediction-of-the-likelihood-of-metabolic-drug-interactions-in-paediatric-population-and-studying-disparities-in-pharmacokinetics-between-children-and-adults(1fdefe9a-037a-4738-b92a-5904a60960db).html.
Texte intégralLivres sur le sujet "Pharmacokinetic interactions"
Kiang, Tony K. L., Kyle John Wilby et Mary H. H. Ensom. Clinical Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antimalarials. Cham : Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-10527-7.
Texte intégralKiang, Tony K. L., Kyle John Wilby et Mary H. H. Ensom, dir. Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antiretroviral Drugs. Singapore : Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-10-2113-8.
Texte intégralBartle, W. R., V. Braun, J. M. Dietschy, Y. Emori, M. Hagiwara, H. Hidaka, S. Imajoh et al. Regulation of Plasma Low Density Lipoprotein Levels Biopharmacological Regulation of Protein Phosphorylation Calcium-Activated Neutral Protease Microbial Iron Transport Pharmacokinetic Drug Interactions. Berlin, Heidelberg : Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-72902-7.
Texte intégralDavid, Rodrigues A., dir. Drug-drug interactions. New York : M. Dekker, 2002.
Trouver le texte intégralDavid, Rodrigues A., dir. Drug-drug interactions. 2e éd. New York : Informa Healthcare, 2008.
Trouver le texte intégralHuang, L. Evaluation of the potential pharmacokinetic interaction between naproxen and zidovudine. [Ottawa : Ottawa General Hospital, 1991.
Trouver le texte intégralMultiple chemical interactions. Chelsea, Mich : Lewis Publishers, 1991.
Trouver le texte intégralRitschel, W. A. Handbook of basic pharmacokinetics-- including clinical applications. 6e éd. Washington, D.C : American Pharmacists Association, 2004.
Trouver le texte intégralRitschel, W. A. Handbook of basic pharmacokinetics ... including clinical applications. 7e éd. Washington, D.C : American Pharmacists Association, 2009.
Trouver le texte intégralRitschel, W. A. Handbook of basic pharmacokinetics-- including clinical applications. 3e éd. Hamilton, IL : Drug Intelligence Publications, 1986.
Trouver le texte intégralChapitres de livres sur le sujet "Pharmacokinetic interactions"
Bartle, W. R., S. E. Walker et N. E. Winslade. « Pharmacokinetic Drug Interactions ». Dans Progress in Clinical Biochemistry and Medicine, 101–31. Berlin, Heidelberg : Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-72902-7_5.
Texte intégralWittwer, Erica D., et Wayne T. Nicholson. « Pharmacokinetic Interactions : Core Concepts ». Dans A Case Approach to Perioperative Drug-Drug Interactions, 15–22. New York, NY : Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4614-7495-1_3.
Texte intégralMukherjee, Biswajit. « Pharmacokinetic Drug–Drug Interactions ». Dans Pharmacokinetics : Basics to Applications, 145–55. Singapore : Springer Singapore, 2022. http://dx.doi.org/10.1007/978-981-16-8950-5_7.
Texte intégralRenton, Kenneth W. « Cytokines and Pharmacokinetic Drug Interactions ». Dans Methods in Pharmacology and Toxicology, 275–96. Totowa, NJ : Humana Press, 2007. http://dx.doi.org/10.1007/978-1-59745-350-9_14.
Texte intégralKiang, Tony K. L., Kyle John Wilby et Mary H. H. Ensom. « Pharmacokinetic Drug Interactions Affecting Antimalarials ». Dans Clinical Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antimalarials, 27–55. Cham : Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-10527-7_4.
Texte intégralMarkowitz, John S., et Kennerly S. Patrick. « Pharmacokinetic and Pharmacodynamic Drug Interactions ». Dans Attention Deficit Hyperactivity Disorder, 529–50. Totowa, NJ : Humana Press, 2005. http://dx.doi.org/10.1385/1-59259-891-9:529.
Texte intégralHuang, Shiew-Mei. « Drug-Drug Interactions ». Dans Applications of Pharmacokinetic Principles in Drug Development, 307–31. Boston, MA : Springer US, 2004. http://dx.doi.org/10.1007/978-1-4419-9216-1_10.
Texte intégralLewis, D. F. V. « Modelling Human Cytochrome P450-Substrate Interactions ». Dans Pharmacokinetic Challenges in Drug Discovery, 235–48. Berlin, Heidelberg : Springer Berlin Heidelberg, 2002. http://dx.doi.org/10.1007/978-3-662-04383-7_12.
Texte intégralIeuter, Rachel C. « Pharmacokinetic Drug-Drug Interactions with Warfarin ». Dans Oral Anticoagulation Therapy, 221–27. Cham : Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-54643-8_32.
Texte intégralBack, D. J., et M. L’E Orme. « Pharmacokinetic Drug Interactions with Oral Contraceptives ». Dans Steroid Contraceptives and Women’s Response, 103–23. Boston, MA : Springer US, 1994. http://dx.doi.org/10.1007/978-1-4615-2445-8_10.
Texte intégralActes de conférences sur le sujet "Pharmacokinetic interactions"
Moitra, Abha, Ravi Palla, Luis Tari et Mukkai Krishnamoorthy. « Semantic Inference for Pharmacokinetic Drug-Drug Interactions ». Dans 2014 IEEE International Conference on Semantic Computing (ICSC). IEEE, 2014. http://dx.doi.org/10.1109/icsc.2014.36.
Texte intégralEgenlauf, Benjamin, Johanna Ohnesorge, Satenik Harutyunova, Nicola Benjamin, Christine Fischer, Yeliz Enderle, Jürgen Burhenne et al. « Pharmacokinetic interactions in different combinations of pulmonary arterial hypertension treatment ». Dans ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa2397.
Texte intégralKulanthaivel, Palaniappan, Daruka Mahadevan, P. Kellie Turner, Jane Royalty, Wee Teck Ng, Ping Yi, Jessica Rehmel, Kenneth Cassidy et Jill Chappell. « Abstract CT153 : Pharmacokinetic drug interactions between abemaciclib and CYP3A inducers and inhibitors ». Dans Proceedings : AACR 107th Annual Meeting 2016 ; April 16-20, 2016 ; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-ct153.
Texte intégralHunta, Sathien, et Panchit Longpradit. « Pharmacokinetic simulation for prediction of drug-drug interactions based on agent based modeling ». Dans 2018 International Conference on Digital Arts, Media and Technology (ICDAMT). IEEE, 2018. http://dx.doi.org/10.1109/icdamt.2018.8376508.
Texte intégralKOLCHINSKY, A., A. LOURENÇO, L. LI et L. M. ROCHA. « EVALUATION OF LINEAR CLASSIFIERS ON ARTICLES CONTAINING PHARMACOKINETIC EVIDENCE OF DRUG-DRUG INTERACTIONS ». Dans Proceedings of the Pacific Symposium. WORLD SCIENTIFIC, 2012. http://dx.doi.org/10.1142/9789814447973_0040.
Texte intégralSchneider, Elena, Patrick Hanafin et Gauri Rao. « A retrospective observational study : Bidirectional pharmacokinetic interactions between ivacaftor-lumacaftor in cystic fibrosis ». Dans ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.362.
Texte intégralPawaskar, Dipti K., Robert Straubinger, Gerald Fetterly, Wen Ma et William Jusko. « Abstract 27 : Physiologically based pharmacokinetic model for interactions of sorafenib and everolimus in mice ». Dans Proceedings : AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011 ; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-27.
Texte intégralYang, Xiaoxia, Hofmeister C. Craig, Darlene M. Rozewski, Seungsoo Lee, Ping Chen, Amy J. Johnson, Zhongfa Liu et al. « Abstract 5473 : The contribution of P-glycoprotein to clinical pharmacokinetic interactions between lenalidomide and temsirolimus ». Dans Proceedings : AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011 ; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-5473.
Texte intégralSidharta, P. N., P. L. M. van Giersbergen, Michael Wolzt et Jasper Dingemanse. « Lack Of Clinically Relevant Pharmacokinetic Interactions Between The Dual Endothelin Receptor Antagonist Macitentan And Sildenafil In Healthy Subjects ». Dans American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a4802.
Texte intégralGeorges, G., A. Lucardie, C. Garofalo, C. Beaudot et M. Cella. « Pharmacokinetic/Pharmacodynamic Interactions Between Extrafine Beclomethasone Dipropionate and Formoterol Fumarate Components of a Fixed-Dose Combination for Asthma and COPD ». Dans American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4528.
Texte intégral